DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20150694

Levonorgestrel intrauterine system: A first line medical therapy for idiopathic heavy menstrual bleeding

P.C. Mahapatra, Anupam Kapur, Asha Baxi, Aruna Kekre, Geeta Mediratta, Jaishree Gajaraj

Abstract


Heavy menstrual bleeding or menorrhagia is a common menstrual disorder. Currently, both medical and surgical treatment options are available for the management of heavy menstrual bleeding. Hysterectomy, one of the surgical treatment options is associated with risks and is a costly procedure. Medical treatment may be preferred for the management of heavy menstrual bleeding. Oral medical treatments have various limitations for their use. For instance, cost is a limiting factor for tranexamic acid. Limited data is available to support the effectiveness of oral contraceptives. Poor patient compliance and intolerable adverse events are some other limitations especially in long term use. Levonorgestrel intrauterine system (LNG-IUS) is one of the common medical modalities in the management of heavy menstrual bleeding. LNG-IUS has been compared with other medical options like tranexamic acid, mefenamic acid, combined estrogen-progestogen, or progesterone alone, cyclic oral medroxyprogesterone acetate (MPA) oral norethisterone and low-dose combined oral contraceptive. LNG-IUS is more effective than usual medical treatment and also reduces the effect of heavy menstrual bleeding on quality of life. Similarly, it has shown similar therapeutic effects compared to endometrial ablation. Based on its efficacy, convenience and cost of therapy, it can be considered as the first line medical therapy for the management of heavy menstrual bleeding.


Keywords


Efficacy, Levonorgestrel, Menorrhagia

Full Text:

PDF

References


Marret H, Fauconnier A. Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152;2:133-7.

Magon N, Chauhan M, Goel P, Malik S, Kapur K, Kriplani A, et al. Levonorgestrel intrauterine system: Current role in management of heavy menstrual bleeding. J Midlife Health. 2013;4:8–15.

Munro MG, Critchley HOD, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology and Obstetrics. 2011;113:3–13.

Harlow SD, Campbell OMR. Epidemiology of menstrual disorders in developing countries:a systematic review BJOG: an International Journal of Obstetrics and Gynaecology. 2004;111:6-16.

Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. International Journal of Gynecology and Obstetrics. 2007;97:190–4.

Grimes DA. Review of management strategies for heavy menstrual bleeding: Summary of the best evidence. Supplement to OBG Management. 2009;S7-S10.

Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP. Evaluation and Management of Abnormal Uterine Bleeding in Premenopausal Women. Am Fam Physician. 2012;85:35-43.

Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113:1104-16.

Stewart A, Cummins C, Gold L. Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. British Journal of Obstetrics and Gynaecology. 2001;108:74-86.

Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstetricia et Gynecologica Scandinavica. 2012; 91:3–9.

Nelson AL. LNG-IUS: First-line therapy for idiopathic heavy menstrual bleeding. The Female Patient. 2010:3:39-43.

Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998;105:592-8.

Monterio I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1). Contraception. 2002;65:325-8.

Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013;368:128-37.

Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, DeSanctis Y, Jensen J. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception. 2012;86:452–7.

Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112:126–30.

Pakarinen P, Luukkainen T, Laine H, Lahteenmaki P. The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation. Hum Reprod. 1995;10:2390–4.

Lee BS, Lin X, Asif S, Kraemer P, Hanisch JU, Inki P. Levonorgestrel-releasing intrauterine system versus conventional medical therapy for heavy menstrual bleeding in the Asia-Pacific region. Int J Gynecol Obstet, 2013.

Kumar Sushil , Antony ZK, Mohindra V, Kapur A. Therapeutic use of LNG intrauterine system (Mirena) for menorrhagia due to benign lesions – An alternative to hysterectomy? J Obstet Gynecol. 2005;6:541-3.

Gupta B, Mittal S, Misra R, Deka D, Dadhwal V. Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding. Int J Gynaecol Obstet. 2006;95:26106.

Chattopdhyay B, Nigam A, Goswami S, Chakravarty PS. Clinical outcome of Levonorgestrel Intra-Uterine system in idiopathic menorrhagia. European Review for Medical and Pharmacological Sciences. 2011;15:764-8.

Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. International Journal of Gynecology and Obstetrics. 2012;116:35–8.

Desai RM. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Midlife Health. 2012;3:20-3.

Mansukhani N, Unni J, Dua M, Darbari R, Malik S, Verma S et al. Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding? J Midlife Health. 2013;4:31-5.

Xiao B, Wu S-C, Chong J, Zeng T, Han L-H, Luukkainen T. Therapeutic effects of the levonorgestrel releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertility and Sterility. 2003;79:963-9.

Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E. The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet. 2012;285:117–21.

Matteson KA, Rahn DD, Wheeler TL, Casiano E, Siddiqui NY, Harvie HS et al. Nonsurgical management of heavy menstrual bleeding- A systematic review. Obstet Gynecol. 2013;0:1–12.

Gowri V, Mathew M. Ultrasound Location of Misplaced Levonorgestrel Releasing Intrauterine System (LNG-IUS) – is it easy? Oman Med J. 2009;24:54–5.

Shambhu S, Pappas M. The “lost” Mirena: What investigations are required ? An intraperitoneal levonorgestrel-releasing intrauterine system following uterine perforation: Case report. BMJP. 2009;2:38-40.